

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/159182 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 47/68 (2017.01)
A61K 41/00 (2020.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/062822

(22) International Filing Date:

17 February 2023 (17.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/311,924 18 February 2022 (18.02.2022) US

(71) Applicant: **RAKUTEN MEDICAL, INC.** [US/US];
11080 Roselle Street, San Diego, California 92121 (US).

(72) Inventors: **STEINIGER, Sebastian**; 11080 Roselle Street,
San Diego, California 92121 (US). **SUSLOV, Nikolai**;
11080 Roselle Street, San Diego, California 92121 (US).


TEPLYAKOV, Alexey; 11080 Roselle Street, San Diego,
California 92121 (US). **THORNE, Amy**; 11080 Roselle
Street, San Diego, California 92121 (US). **LAPETODA,**
Jason; 11080 Roselle Street, San Diego, California 92121
(US). **HOEY, Robert J.**; 11080 Roselle Street, San Diego,
California 92121 (US).

(74) Agent: **AHN, Sejin** et al.; Morrison & Foerster LLP,
12531 High Bluff Drive, Suite 100, San Diego, California
92130-2040 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODY MOLECULES, ENCODING POLYNUCLEOTIDES,
AND METHODS OF USE

FIG. 8A



(57) Abstract: Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions and articles of manufacture containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the anti-PD-L1 antibodies, fragments, and conjugates specifically bind to human PD-L1. Among the anti-PD-L1 antibodies are human antibodies and humanized antibodies. Also provided are methods and uses employing the provided anti-PD-L1 antibodies, antigen-binding fragments, and conjugates such for treatment of human patients.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*